• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

未治疗的肝细胞癌的生存情况:一项全国性队列研究。

Survival in untreated hepatocellular carcinoma: A national cohort study.

机构信息

Division of Cancer Control & Policy, National Cancer Control Institute, National Cancer Center, Goyang, South Korea.

Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea.

出版信息

PLoS One. 2021 Feb 4;16(2):e0246143. doi: 10.1371/journal.pone.0246143. eCollection 2021.

DOI:10.1371/journal.pone.0246143
PMID:33539397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7861368/
Abstract

This study aimed to analyze the proportion, characteristics and prognosis of untreated hepatocellular carcinoma (HCC) patients in a large representative nationwide study. A cohort study was conducted using the National Health Insurance Service (NHIS) database in Korea. A total of 63,668 newly-diagnosed HCC patients between January 2008 and December 2013 were analyzed. Patients were categorized into treatment group and no treatment group using claim codes after HCC diagnosis. The proportion of untreated HCC patients was 27.6%, decreasing from 33.4% in 2008 to 24.8% in 2013. Compared to treated patients, untreated patients were more likely to be older (P < 0.001), female (P < 0.01), to have a distant SEER stage (P < 0.001), severe liver disease (P < 0.001), and lower income (P < 0.001). The fully-adjusted hazard ratio for all-cause mortality comparing untreated to treated patients was 3.11 (95% CI, 3.04-3.18). The risk of mortality was higher for untreated patients in all pre-defined subgroups, including those with distant SEER stage and those with severe liver disease. About one fourth of newly diagnosed HCC patients did not receive any HCC-specific treatment. Untreated patients showed higher risk of mortality compared to treated patients in all subgroups. Further studies are needed to identify obstacles for HCC treatment and to improve treatment rates.

摘要

本研究旨在通过一项大型全国代表性研究分析未经治疗的肝细胞癌(HCC)患者的比例、特征和预后。本研究使用韩国国家健康保险服务(NHIS)数据库进行了一项队列研究。分析了 2008 年 1 月至 2013 年 12 月期间新诊断的 63668 例 HCC 患者。根据 HCC 诊断后的理赔代码,将患者分为治疗组和未治疗组。未经治疗的 HCC 患者比例为 27.6%,从 2008 年的 33.4%降至 2013 年的 24.8%。与治疗患者相比,未经治疗的患者年龄更大(P<0.001)、女性(P<0.01)、远处 SEER 分期(P<0.001)、严重肝脏疾病(P<0.001)和收入较低(P<0.001)。未经治疗与治疗患者全因死亡率的完全调整风险比为 3.11(95%CI,3.04-3.18)。在所有预先定义的亚组中,包括远处 SEER 分期和严重肝脏疾病患者,未经治疗的患者的死亡风险更高。约四分之一的新诊断 HCC 患者未接受任何 HCC 特异性治疗。未经治疗的患者在所有亚组中的死亡风险均高于治疗患者。需要进一步研究以确定 HCC 治疗的障碍,并提高治疗率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d9/7861368/8770ad9271b3/pone.0246143.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d9/7861368/2ef9fbbdfd55/pone.0246143.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d9/7861368/5ee60cfda456/pone.0246143.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d9/7861368/8770ad9271b3/pone.0246143.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d9/7861368/2ef9fbbdfd55/pone.0246143.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d9/7861368/5ee60cfda456/pone.0246143.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39d9/7861368/8770ad9271b3/pone.0246143.g003.jpg

相似文献

1
Survival in untreated hepatocellular carcinoma: A national cohort study.未治疗的肝细胞癌的生存情况:一项全国性队列研究。
PLoS One. 2021 Feb 4;16(2):e0246143. doi: 10.1371/journal.pone.0246143. eCollection 2021.
2
Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.早期肝细胞癌患者在获得医疗服务和生存方面的种族/族裔差异。
Arch Surg. 2010 Dec;145(12):1158-63. doi: 10.1001/archsurg.2010.272.
3
Association of socioeconomics, surgical therapy, and survival of early stage hepatocellular carcinoma.社会经济学、手术治疗与早期肝细胞癌生存率的关联
J Surg Res. 2017 Apr;210:253-260. doi: 10.1016/j.jss.2016.11.042. Epub 2016 Nov 30.
4
Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study.使用巴塞罗那临床肝癌分期 C 期肝细胞癌的新亚分期系统进行预后评估:一项全国性研究。
Liver Int. 2019 Jun;39(6):1109-1119. doi: 10.1111/liv.14117. Epub 2019 May 7.
5
Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection.核苷类似物与肝切除术后乙型肝炎病毒相关肝细胞癌复发的风险之间的关联。
JAMA. 2012 Nov 14;308(18):1906-14. doi: 10.1001/2012.jama.11975.
6
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.恩替卡韦与替诺福韦治疗慢性乙型肝炎患者的肝细胞癌风险:一项韩国全国队列研究。
JAMA Oncol. 2019 Jan 1;5(1):30-36. doi: 10.1001/jamaoncol.2018.4070.
7
Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area.巴塞罗那临床肝癌分期系统与乙型肝炎病毒流行地区未经治疗的肝细胞癌患者的生存率
J Gastroenterol Hepatol. 2015 Apr;30(4):696-705. doi: 10.1111/jgh.12788.
8
Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study.根治性切除术后肝细胞癌患者使用二甲双胍与癌症特异性死亡率的关联:一项基于全国人群的研究。
Medicine (Baltimore). 2016 Apr;95(17):e3527. doi: 10.1097/MD.0000000000003527.
9
Does low income effects 5-year mortality of hepatocellular carcinoma patients?低收入是否会影响肝细胞癌患者的 5 年死亡率?
Int J Equity Health. 2021 Sep 1;20(1):151. doi: 10.1186/s12939-021-01498-z.
10
Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database.根据基于监测、流行病学和最终结果(SEER)数据库的5年生存分析,将甲胎蛋白(AFP)纳入BCLC C期肝细胞癌的亚分类
Oncotarget. 2016 Dec 6;7(49):81389-81401. doi: 10.18632/oncotarget.13232.

引用本文的文献

1
Social Inequities in the Survival of Liver Cancer: A Nationwide Cohort Study in Korea, 2007-2017.社会不平等对肝癌生存率的影响:韩国 2007-2017 年全国队列研究。
J Korean Med Sci. 2024 Apr 1;39(12):e130. doi: 10.3346/jkms.2024.39.e130.
2
Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes.肝癌发病率和治疗效果的种族差异。
Cancer Rep (Hoboken). 2023 Sep;6 Suppl 1(Suppl 1):e1821. doi: 10.1002/cnr2.1821. Epub 2023 Jun 21.
3
Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data.

本文引用的文献

1
Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?21 世纪的肝细胞癌监测:挽救生命还是造成伤害?
Clin Mol Hepatol. 2019 Sep;25(3):264-269. doi: 10.3350/cmh.2019.1001. Epub 2019 Mar 4.
2
Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients.多学科方法与改善肝癌患者的生存率相关。
PLoS One. 2019 Jan 14;14(1):e0210730. doi: 10.1371/journal.pone.0210730. eCollection 2019.
3
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.
未经治疗的肝细胞癌患者生存结局的相关因素:一项全国性数据分析
Front Oncol. 2023 Mar 22;13:1142661. doi: 10.3389/fonc.2023.1142661. eCollection 2023.
4
The impact of HIV infection on clinical presentation and mortality among persons with hepatocellular carcinoma in Kampala, Uganda.HIV 感染对乌干达坎帕拉地区肝细胞癌患者临床表现和死亡率的影响。
BMC Infect Dis. 2023 Apr 6;23(1):216. doi: 10.1186/s12879-023-08164-5.
5
Comorbidity Differences by Trajectory Groups as a Reference for Identifying Patients at Risk for Late Mortality in Childhood Cancer Survivors: Longitudinal National Cohort Study.基于轨迹组的合并症差异作为识别儿童癌症幸存者晚期死亡风险患者的参考:纵向全国队列研究。
JMIR Public Health Surveill. 2023 Mar 24;9:e41203. doi: 10.2196/41203.
6
Protein phosphatases regulate the liver microenvironment in the development of hepatocellular carcinoma.蛋白磷酸酶调控肝癌发生发展中的肝微环境。
Exp Mol Med. 2022 Nov;54(11):1799-1813. doi: 10.1038/s12276-022-00883-0. Epub 2022 Nov 15.
7
Proton Beam Therapy for Multifocal Hepatocellular Carcinoma (HCC) Showing Complete Response in Pathological Anatomy After Liver Transplantation.质子束治疗多灶性肝细胞癌(HCC)在肝移植后病理解剖显示完全缓解。
Cureus. 2022 Jun 8;14(6):e25744. doi: 10.7759/cureus.25744. eCollection 2022 Jun.
8
On Efficacy of Microwave Ablation in the Thermal Treatment of an Early-Stage Hepatocellular Carcinoma.微波消融在早期肝细胞癌热治疗中的疗效
Cancers (Basel). 2021 Nov 18;13(22):5784. doi: 10.3390/cancers13225784.
2017年丙型肝炎管理的KASL临床实践指南:慢性丙型肝炎的治疗
Clin Mol Hepatol. 2018 Sep;24(3):169-229. doi: 10.3350/cmh.2018.1004. Epub 2018 Aug 10.
4
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.符合肝细胞癌监测指南与代偿性病毒肝硬化患者的生存时间延长相关:一项多中心队列研究。
Gastroenterology. 2018 Aug;155(2):431-442.e10. doi: 10.1053/j.gastro.2018.04.027. Epub 2018 May 3.
5
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南:肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
6
Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment?
Scand J Gastroenterol. 2018 Jun;53(6):727-733. doi: 10.1080/00365521.2018.1458895. Epub 2018 Apr 3.
7
Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis.对于一大群现实生活中的丙型肝炎肝硬化患者而言,肝细胞癌监测率仍然很低。
BMJ Open Gastroenterol. 2018 Mar 20;5(1):e000192. doi: 10.1136/bmjgast-2017-000192. eCollection 2018.
8
Epidemiology of liver cancer in South Korea.韩国肝癌的流行病学。
Clin Mol Hepatol. 2018 Mar;24(1):1-9. doi: 10.3350/cmh.2017.0112. Epub 2017 Dec 18.
9
Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue.肝癌监测依从性差:一个复杂问题的系统评价和荟萃分析。
Liver Int. 2018 Mar;38(3):503-514. doi: 10.1111/liv.13555. Epub 2017 Sep 9.
10
A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.索拉非尼与节拍化疗治疗巴塞罗那临床肝癌C期且肝功能较差的肝细胞癌的对比研究
Clin Mol Hepatol. 2017 Jun;23(2):128-137. doi: 10.3350/cmh.2016.0071. Epub 2017 May 10.